Financing channel feed – Endpoints News

Financing channel feed

Ronald Crystal's Lexeo Therapeutics pulls in a $100M megaround just nine months after launch

4 years ago

A few months into his new role at Attralus, ex-Purdue chief Mark Timney leads the biotech to a $116M round

4 years ago

One of Tachi's newly born legacy biotechs raises $135M and enlists an A-list board to advance late-stage vaccine

4 years ago

'Like a kid in a candy shop': Michael Ehlers gets behind RNA 'copy machine' tech

4 years ago

Roche schizophrenia drug that failed PhIII gets a new life in rare disorder as OrbiMed leads $90M for startup

4 years ago

A next-gen IL-2 challenger bags a megaround with RA Capital on board to accelerate 'modular' drug platform

4 years ago

Antiviral nasal drop maker does the Nasdaq shuffle as part of minor SPAC reverse merger

4 years ago

A Novartis castoff drug gets new life at an Atlas-backed startup looking to blaze a trail in obesity

4 years ago

Big money: Flagship's uber-platform play Laronde rakes in $440M to chase programmable 'eRNA'

4 years ago

Backed by Eli Lilly, a little-known and secretive Chinese biotech fills the tank as it heads to the clinic

4 years ago

Kevin Judice plays DiCE, pivoting from a $60M raise straight to the big S-1 filing

4 years ago

After pandemic delay and a South Korean deal, Boston-area biotech raises Series B with sights on IPO

4 years ago

A Bristol Myers-backed biotech wants to treat heart disease with non-coding RNAs. It's one step closer to proof-of-concept

4 years ago

What's Kevin Judice cooking up at DiCE now that he's stashed an extra $60M?

4 years ago

Former Blueprint and Peloton vets team up to take on big players in growing hunt for a new type of small molecule

4 years ago

RA Capital aims to take preclinical biotech to Nasdaq as Tyra files S-1 during summer lull

4 years ago

China's Abogen, a small mRNA upstart, sets a biotech record with mammoth $700M Series C

4 years ago

A transpacific biotech rushes toward the clinic with a twist on classic protein degraders

4 years ago

Stuart Schreiber’s bid to tackle huge class of crucial proteins nabs another $50M

4 years ago

Vigil raises $90M in neuroscience 'renaissance.' Is an IPO around the corner?

4 years ago

Touting CD161 as a test case for single-cell tech, Longwood-backed Immunitas bags $58M for next-gen I/O work

4 years ago

Magic mushrooms and 'toad venom' get this British biotech an oversubscribed Series B

4 years ago

After attracting multiple Chinese pharma partners, XtalPi grabs another $400M to refine AI for drug discovery

4 years ago

A unicorn bags another $220M to fund its plans to upend the clinical trial process

4 years ago

First page Previous page 67 68 697071 72 73 Next page Last page